Capricor Therapeutics Inc. (Nasdaq: CAPR) has released a new investor presentation detailing updates on its lead program, deramiocel, for the treatment of Duchenne muscular dystrophy (DMD). The presentation outlines the company's recent progress, including the completion of a pre-license inspection, positive topline results from the HOPE-3 Phase 3 clinical trial announced in December 2025, and ongoing regulatory interactions. Capricor plans to submit additional documents to the FDA with the goal of lifting a previously issued Complete Response Letter (CRL), targeting a potential PDUFA decision in the second half of 2026. The company also provides a financial overview, reporting a proforma cash balance of $335 million and a runway of approximately 2-3 years based on its current operating plan. Capricor highlights potential milestone payments from its U.S. distribution agreement with NS Pharma and the potential sale of a priority review voucher if received. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Capricor Therapeutics Inc. published the original content used to generate this news brief on February 05, 2026, and is solely responsible for the information contained therein.